| Literature DB >> 32831140 |
Junyong Li1,2, Yanbin Zhu1,2, Kuo Zhao1,2, Junzhe Zhang1,2, Hongyu Meng1,2, Zhucheng Jin1,2, Jiangtao Ma1,2, Yingze Zhang3,4.
Abstract
BACKGROUND: Surgical site infection (SSI) was the most common complication of tibial plateau fracture after open reduction and internal fixation (ORIF). Severe infections even required repeat surgeries, which would cause serious psychological harm to patients and increased the economic burden of treatment. In order to identify the characteristics of the SSI and to avoid the occurrence of SSI, we conducted a prospective study to investigate the incidence and independent risk factors of SSI after ORIF for closed tibial plateau fractures in adults.Entities:
Keywords: Closed tibial plateau fractures; Incidence; Risk factors; Surgical site infection
Mesh:
Substances:
Year: 2020 PMID: 32831140 PMCID: PMC7444203 DOI: 10.1186/s13018-020-01885-2
Source DB: PubMed Journal: J Orthop Surg Res ISSN: 1749-799X Impact factor: 2.359
Fig. 1The flow chart for the selection of study participants
Comparison of continuous variables in patients with and without SSI
| Variables | Patient without SSI (mean, standard deviation) ( | Patient with SSI (mean, standard deviation) ( | |
|---|---|---|---|
| Age (years) | 45.6 (13.6) | 43.0 (11.8) | 0.347 |
| Preoperative stay (days) | 7.3 (6.9) | 14.5 (17.9) | 0.000* |
| Intraoperative blood loss (ml) | 280.2 (267.4) | 434.0 (370.7) | 0.005* |
| Operation duration (minutes) | 147.4 (64.7) | 195.8 (68.4) | 0.000* |
| Hospital stay (days) | 19.3 (22.5) | 43.4 (46.5) | 0.000* |
significant variables
Univariate analyses of risk factors associated with SSI after ORIF of closed tibial plateau fracture
| Variables | Number (%) of SSI ( | Number (%) of non-SSI ( | |
|---|---|---|---|
| Gender (male) | 20 (80.0) | 677 (62.5) | 0.074 |
| Diabetes mellitus | 2 (8.0) | 150 (13.8) | 0.401 |
| Hypertension | 2 (8.0) | 197 (18.2) | 0.189 |
| Cerebrovascular disease | 1 (4.0) | 18 (1.7) | 0.373 |
| Chronic heart disease | 1 (4.0) | 51 (4.7) | 0.868 |
| History of any surgery | 1 (4.0) | 118 (10.9) | 0.271 |
| Allergy to any medications | 3 (12.0) | 138 (12.7) | 0.912 |
| Living area | 0.827 | ||
| Rural | 15 (60.0) | 673 (62.1) | |
| Urban | 10 (40.0) | 410 (37.9) | |
| Preoperative duration (days) | 0.000* | ||
| 1–7 | 8 (32.0) | 723 (66.8) | |
| >7 | 17 (68.0) | 360 (33.2) | |
| Anesthesia (general) | 10 (40.0) | 450 (41.6) | 0.876 |
| Number of fracture | 0.057 | ||
| 1 | 11 (44.0) | 679 (62.7) | |
| ≥2 | 14 (56.0) | 404 (37.3) | |
| Mechanism (high-energy) | 17 (68.0) | 676 (62.4) | 0.569 |
| Current smoking | 4 (16.0) | 147 (13.6) | 0.727 |
| Alcohol consumption | 2 (8.0) | 101 (9.3) | 0.821 |
| Bone grafting (yes) | 13 (52.0) | 225 (20.8) | 0.000* |
| Bone graft type | 0.000* | ||
| Autograft | 8 (32.0) | 113 (10.4) | |
| Allograft | 5 (20.0) | 112 (10.3) | |
| Operative duration (minutes) | 0.001* | ||
| 1–120 | 3 (12.0) | 505 (46.6) | |
| >120 | 22 (88.0) | 578 (53.4) | |
| Intraoperative blood loss (ml) | 0.000* | ||
| 1–400 | 15 (60.0) | 931 (86.0) | |
| >400 | 10 (40.0) | 152 (14.0) | |
| ASA class | 0.942 | ||
| I | 3 (12.0) | 155 (14.3) | |
| II | 18 (72.0) | 768 (70.9) | |
| III or above | 4 (16.0) | 160 (14.8) | |
| Prophylactic antibiotics use | 22 (88.0) | 1038 (95.8) | 0.057 |
| Postoperative antibiotics use | 22 (88.0) | 1005 (92.8) | 0.362 |
| Fixation type | 0.774 | ||
| Plate and screws | 23 (92.0) | 1012 (93.4) | |
| Screws only | 2 (8.0) | 71 (6.6) | |
| Intraoperative blood transfusion | 6 (24.0) | 106 (9.8) | 0.020* |
| Fracture type (Schartzker) | 0.000* | ||
| I–IV | 6 (24.0) | 835 (77.1) | |
| V–VI | 19 (76.0) | 248 (22.9) | |
| Age (years) | 0.461 | ||
| 18–44 | 15 (60.0) | 514 (47.5) | |
| 45–64 | 8 (32.0) | 462 (42.7) | |
| ≥65 | 2 (8.0) | 107 (9.9) | |
| BMI (kg/m2) | 0.361 | ||
| 18.5–23.9 | 9 (36.0) | 473 (43.7) | |
| <18.5 | 1 (4.0) | 11 (1.0) | |
| 24–27.9 | 8 (32.0) | 383 (35.4) | |
| ≥28.0 | 7 (28.0) | 216 (19.9) | |
| TP (<60 g/L) | 11 (44.0) | 285 (26.3) | 0.048* |
| ALB (<35 g/L) | 12 (48.0) | 224 (20.7) | 0.001* |
| GLOB (<20 g/L) | 4 (16.0) | 157 (14.5) | 0.833 |
| A/G values | 0.009* | ||
| 1.2–2.4 | 18 (72.0) | 970 (89.6) | |
| <1.2 | 6 (24.0) | 81 (7.5) | |
| >2.4 | 1 (4.0) | 32 (3.0) | |
| ALT (>40 U/L) | 12 (48.0) | 199 (18.4) | 0.000* |
| AST (>40 U/L) | 11 (44.0) | 140 (12.9) | 0.000* |
| TBIL (>21 μmol/L) | 4 (16.0) | 91 (8.4) | 0.180 |
| DBIL (>6 μmol/L) | 9 (36) | 302 (27.9) | 0.372 |
| IBIL (>14 μmol/L) | 6 (24) | 162 (15.0) | 0.213 |
| ALP (>100 U/L) | 3 (12.0) | 50 (4.6) | 0.087 |
| GGT (>60 U/L) | 7 (28.0) | 183 (16.9) | 0.145 |
| CHE (>12 kU/L) | 1 (4.0) | 27 (2.5) | 0.635 |
| TBA (>10 μmol/L) | 2 (8.0) | 65 (6.0) | 0.679 |
| HCRP (>8 mg/L) | 17 (68.0) | 732 (67.6) | 0.965 |
| LDH (>250 U/L) | 10 (40.0) | 244 (22.5) | 0.040* |
| HBDH (>182 U/L) | 5 (20.0) | 183 (16.9) | 0.683 |
| TC (>5.2 mmol/L) | 1 (4.0) | 127 (11.7) | 0.232 |
| TG (>1.7 mmol/L) | 3 (12.0) | 186 (17.2) | 0.496 |
| HDL-C (<1.1 mmol/L) | 12 (48.0) | 435 (40.2) | 0.430 |
| LDL-C (>3.37 mmol/L) | 2 (8.0) | 148 (13.7) | 0.413 |
| VLDL (>0.78 mmol/L) | 2 (8.0) | 181 (16.7) | 0.246 |
| Na+ (<135 mmol/L) | 13 (52.0) | 320 (29.5) | 0.015* |
| K+ (mmol/L) | 0.772 | ||
| 3.5–5.5 | 24 (96.0) | 1002 (92.5) | |
| <3.5 | 1 (4.0) | 70 (6.5) | |
| >5.5 | 0 (0.0) | 11 (1.0) | |
| CL- (mmol/L) | 0.151 | ||
| 99–110 | 18 (72.0) | 929 (85.8) | |
| <99 | 6 (24.0) | 135 (12.5) | |
| >110 | 1 (4.0) | 19 (1.8) | |
| TCO2 (mmol/L) | 0.475 | ||
| 20–30 | 25 (100.0) | 1022 (94.4) | |
| <20 | 0 (0.0) | 17 (1.6) | |
| >30 | 0 (0.0) | 44 (4.1) | |
| GLU (>6.1 mmol/L) | 9 (36.0) | 373 (34.4) | 0.871 |
| UREA (>8 mmol/L) | 0 (0.0) | 74 (6.8) | 0.176 |
| UA (>upper limit) | 1 (4.0) | 85 (7.8) | 0.477 |
| WBC (>10*109/L) | 15 (60.0) | 344 (31.8) | 0.003* |
| NEUT (1.8–6.3*109/L) | 0.281 | ||
| 1.8–6.3 | 9 (36.0) | 556 (51.3) | |
| <1.8 | 0 (0.0) | 6 (0.6) | |
| >6.3 | 16 (64.0) | 521 (48.1) | |
| LYM (<1.1*109/L) | 5 (20.0) | 303 (28.0) | 0.379 |
| MON (>0.6*109/L) | 15 (60.0) | 658 (60.8) | 0.939 |
| RBC <lower limit | 17 (68.0) | 436 (40.3) | 0.005* |
| HGB <lower limit | 21 (84.0) | 587 (54.2) | 0.003* |
| HCT <lower limit | 22 (88.0) | 675 (62.3) | 0.009* |
| MCV (fL) | 0.365 | ||
| 82–100 | 25 (100.0) | 1002 (92.5) | |
| <82 | 0 (0.0) | 40 (3.7) | |
| >100 | 0 (0.0) | 41 (3.8) | |
| MCH (pg) | 0.564 | ||
| 27–34 | 24 (96.0) | 990 (91.4) | |
| <27 | 0 (0.0) | 47 (4.3) | |
| >34 | 1 (4.0) | 46 (4.2) | |
| MCHC (g/L) | 0.423 | ||
| 316-354 | 23 (92.0) | 1008 (93.1) | |
| <316 | 0 (0.0) | 32 (3.0) | |
| >354 | 2 (8.0) | 43 (4.0) | |
| PDW (%) | 0.557 | ||
| 12–18.1 | 21 (84.0) | 945 (87.3) | |
| <12 | 4 (16.0) | 116 (10.7) | |
| >18.1 | 0 (0.0) | 22 (2.0) | |
| D-Dimer (>0.5 mg/L) | 20 (80.0) | 650 (60.0) | 0.043* |
| AG (mmol/L) | 0.024* | ||
| 8–16 | 16 (64.0) | 854 (78.9) | |
| <8 | 7 (28.0) | 212 (19.6) | |
| >16 | 2 (8.0) | 17 (1.6) | |
| OSM < 260 mOsm/L | 6 (24.0) | 104 (9.6) | 0.017* |
| CA (mmol/L) | 0.480 | ||
| 2.11–2.52 | 17 (68.0) | 822 (75.9) | |
| <2.11 | 8 (32.0) | 246 (22.7) | |
| >2.52 | 0 (0.0) | 15 (1.4) | |
| P (mmol/L) | 0.027* | ||
| 0.85–1.51 | 17 (68.0) | 932 (86.1) | |
| <0.85 | 2 (8.0) | 53 (4.9) | |
| >1.51 | 6 (24.0) | 98 (9.0) | |
| Mg (mmol/L) | 0.008* | ||
| 0.75–1.02 | 18 (72.0) | 941 (86.9) | |
| <0.75 | 6 (24.0) | 79 (7.3) | |
| >1.02 | 1 (4.0) | 63 (5.8) | |
| PLT (10*109/L) | 0.905 | ||
| 125–350 | 20 (80.0) | 901 (83.2) | |
| <125 | 1 (4.0) | 41 (3.8) | |
| >350 | 4 (16.0) | 141 (13.0) |
Abbreviation and notes: ASA American Society of Anesthesiologists; BMI body mass index; RBC red blood cell, reference range: female 3.5–5.0*1012/L; males 4.0–5.5*1012/L. HGB hemoglobin, reference range: females 110–150 g/L; males 120–160 g/L; HCT hematocrit, 40–50%; MCV mean corpuscular volume; MCH mean corpuscular hemoglobin; MCHC mean corpuscular hemoglobin concentration; WBC white blood cell; NEUT neutrophile; LYM lymphocyte; MON mononuclear cell; PLT platelet; 100–300*109/L; TP total protein; ALB albumin; GLOB globulin; A/G values albumin/globulin; ALT alanine transaminase; AST aspartate aminotransferase; TBIL total bilirubin; DBIL direct bilirubin; IBIL indirect bilirubin; ALP alkaline phosphatase; GGT γ-glutamyl transpeptidase; CHE cholinesterase; TBA total bile acid; HCRP hypersensitive c-reactive protein; LDH lactate dehydrogenase; HBDH hydroxybutyrate dehydrogenase; TC total cholesterol; TG triglyceride; HDL-C high-density lipoprotein; LDL-C low-density lipoprotein; VLDL very-low-density lipoprotein; GLU glucose; UREA serum urea; UA, uric acid; RDW red cell distribution width; PDW platelet distribution width; AG anion gap; OSM osmotic pressure
*Significant variables
Multivariate analysis of factors associated with SSI after ORIF of closed tibial plateau fracture
| Variables | OR | 95%CI (lower limit) | 95%CI (upper limit) | |
|---|---|---|---|---|
| Preoperative duration | 2.282 | 0.880 | 5.915 | 0.090 |
| Bone grafting(yes) | 0.002* | |||
| Autograft | 6.380 | 2.155 | 18.886 | 0.001* |
| Allograft | 3.215 | 1.009 | 10.247 | 0.048* |
| Operative duration (minutes) | 3.544 | 0.958 | 13.108 | 0.058 |
| Fracture type (Schartzker V–VI) | 8.129 | 2.961 | 22.319 | 0.000* |
| AST (>40 U/L) | 5.500 | 2.191 | 13.807 | 0.000* |
| WBC (>10*109/L) | 2.498 | 1.025 | 6.092 | 0.044* |
| AG (mmol/L) | 0.078 | |||
| <8 | 1.878 | 0.694 | 5.082 | 0.214 |
| >16 | 8.194 | 1.101 | 60.980 | 0.040* |
Abbreviation and notes: AST aspartate aminotransferase; WBC white blood cell; AG anion gap
*Significant variables